Tuesday, December 13

1:30 p.m.-1:50 p.m.

Break

Central Lobby

12:00 p.m.-1:30 p.m.

Opening Session
Pearl Ballroom

1:50 p.m.-3:20 p.m.

Concurrent Session 1: Shared Cyberinfrastructure for Cancer Research and

Treatment
Maple Room

Welcome and Opening Remarks

Judy E. Garber, President, American Association for Cancer Research, Philadelphia, PA, USA; Dana-Farber Cancer Institute, Boston, MA, USA

Margaret Foti, CEO, American Association for Cancer Research, Philadelphia, PA, USA

Anil K. Rustgi, University of Pennsylvania, Philadelphia, PA, USA

Keynote Presentations

The State of the Science in India

Maharaj Kishan Bhan, Government of India, Ministry
of Science and Technology,
New Delhi, India

Current and Future Prospects for HPV Vaccination* **Douglas R. Lowy,** National Cancer Institute,

Bethesda, MD, USA

Chairperson: Anil Srivastava, Open Health Systems Laboratory at Johns Hopkins Montgomery County Campus, Rockville, MD, USA

Global cancer grid: Vision and reality* **Anil Srivastava**

Single cell informatics: Applications in stem cells and cancer*

Saumyadipta Pyne, Dana-Farber Cancer Institute, Boston, MA, USA

caBRAF: A caBIG-BRAF coaction for cancer bioinformatics*

Rajendra Joshi, Bioinformatics Resources and Applications Facility, Centre for Development of Advanced Computing, Pune, India

Indo-US partnership to accelerate botanicals and biologics drug development for cancer chemoprevention: In silico drug development model** Nagi Kumar, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Discussion

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

^{**}Short talks from proffered papers.

1:50 p.m.-3:20 p.m.

Concurrent Session 2: Pancreatic Cancer

Royal Room

3:40 p.m.-5:10 p.m. **Concurrent Session 3:**

Lung Cancer

Royal Room

Chairperson: Pramod K. Garg, All India Institute of Medical Sciences, New Delhi, India

Epidemiology, risk factors, and diagnosis of pancreatic cancer*

Pramod K. Garg

Molecular pathogenesis of pancreatic cancer and precursor lesions: Lessons from mice and men* Anirban Maitra, Johns Hopkins University, Baltimore, MD, USA

Minnelide: A novel therapy for pancreatic cancer* Ashok K. Saluja, University of Minnesota, Minneapolis, MN, USA

Embryogenesis meets tumorigenesis: Nodal/Activin signaling drives self-renewal and invasiveness of pancreatic cancer stem cells**

Christopher Heeschen, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Assessing therapeutic responses in pancreatic cancer using genetically engineered mouse models** Mallika Singh, Genentech, Inc., South San Francisco, CA, USA

Discussion

3:20 p.m.-3:40 p.m. **Break**

Central Lobby

Chairperson: Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA

Somatic genome alterations in human lung cancers* Matthew L. Meyerson

Clinical implications of genome sequencing in lung

Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO, USA

Genomic medicine: Therapeutic opportunities for lung cancer in India*

Amit Dutt, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Mumbai, India

Methylation events in lung cancer: Whole-genome explorations of paired tumor and nontumor clinical samples**

Nandita Mullapudi, Albert Einstein College of Medicine, Bronx, NY, USA

Discussion

3:40 p.m.-5:10 p.m.

Concurrent Session 4:

Cancer Genetics Maple Room

Chairperson: Curtis C. Harris, National Cancer Institute, Bethesda, MD, USA

Inflammation and cancer: Interweaving microRNA, innate immune, and p53 networks*

Curtis C. Harris

Nuclear organization: Effect of chromosome dosage?* Kundan Sengupta, Indian Institute of Science Education and Research, Pune, India

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

^{**}Short talks from proffered papers.

Mechanism of chromosomal translocations in leukemia and lymphoma*

Sathees C. Raghavan, Indian Institute of Science,

Bangalore, India

Epigenetic regulation during glioma development* **Kumaravel Somasundaram,** Indian Institute of Science, Bangalore, India

Discussion

5:15 p.m.-6:15 p.m. Meet-the-Expert Session

(Concurrent)
Royal Room

A Role of Natural Products in the Discovery of Antitumor Drugs such as Taxol* Susan Band Horwitz, Albert Einstein College of Medicine, Bronx, NY, USA

5:15 p.m.-6:15 p.m. Meet-the-Expert Session

(Concurrent)
Maple Room

Microenvironment in Hematological Malignancies* Varsha Gandhi, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

6:20 p.m.-6:45 p.m. Day in Review
Pearl Ballroom

Daily wrap-up with Anil K. Rustgi, Pramod K. Garg, Curtis C. Harris, Matthew L. Meyerson, and Anil Srivastava

6:45 p.m.-8:30 p.m. Opening Reception
Central Lobby

Wednesday, December 14

8:00 a.m.-9:30 a.m. Pa

Panel Discussion:
Drug Development and
Clinical Trials in India

Pearl Ballroom

Co-Chairpersons: Lalit Kumar, All India Institute of Medical Sciences, New Delhi, India; and **Pankaj Bhargava,** Sanofi-Aventis, Cambridge, MA, USA

Panelists:

Raghunadharao Digumarti, Nizams Institute of Medical Sciences, Hyderabad, India

Yogendra Kumar Gupta, All India Institute of Medical Sciences, New Delhi, India

Kiran Mazumdar, Biocon Ltd., Bangalore, India

Arvind Pandey, National Institute of Medical Statistics, New Delhi, India

Sanjeeva Reddy, Endo Pharmaceuticals, Chadds Ford, PA, USA

9:30 a.m.-9:50 a.m. Break

Central Lobby

9:50 a.m.-11:40 a.m.

Plenary Session 1: Cancer Genomics

Pearl Ballroom

Co-Chairpersons: Rajiv Sarin, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Hospital, Parel, Mumbai, India; and **Ashok R. Venkitaraman,** University of Cambridge, Cambridge, United Kingdom

Novel, founder, and recurrent germline mutations in high-penetrance cancer genes in South Asians* **Rajiv Sarin**

Genomic alterations in gingivobuccal cancer: Results from whole-exome resequencing*

Partha P. Majumder, National Institute of Biomedical Genomics, Kalyani, India

Interrogating the architecture of cancer genomes* **Peter J. Campbell,** Wellcome Trust Sanger Institute,
Hinxton, United Kingdom

Exploiting tumor suppressor mechanisms that control genome stability in new approaches to cancer therapy*

Ashok R. Venkitaraman

Genome and transcriptome landscape of oral tongue squamous cell carcinoma along with matched potentially malignant lesions**

Binay Panda, Ganit Labs, Bio-IT Centre, Institute of Bioinformatics and Applied Biotechnology, Strand Life Sciences, Bangalore, Karnataka, India

Discussion

11:40 a.m.-1:40 p.m. Poster Session A/Lunch
Prefunction Area

1:50 p.m.-3:40 p.m.

Plenary Session 2: Oral and Head/Neck Cancer

Pearl Ballroom

Co-Chairpersons: E. Hemanth Raj, Apollo Specialty Hospital, Chennai, India; and **Tanuja Teni,** Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Mumbai, India

Therapeutic targeting of critical pathways in head and neck cancer*

Jennifer Rubin Grandis, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Radiation response-related proteins in oral squamous cell carcinomas*

Tanuja Teni

Therapy: Surgery

Anil K. D'Cruz, Tata Memorial Hospital, Mumbai, India

Therapy: Radiation

A. Vasanthan, Cancer Institute, Adyar, Chennai, India

Discussion

3:40 p.m.-4:00 p.m. Break

Central Lobby

4:00 p.m.-5:50 p.m.

Plenary Session 3: Cervical Cancer Pearl Ballroom

Co-Chairpersons: Douglas R. Lowy, National Cancer Institute, Bethesda, MD, USA; and Rita Mulherkar, Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, India

Descriptive epidemiology and prevention of cervical cancer in India*

Rajaraman Swaminathan, Cancer Institute, Adyar, Chennai, India

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

^{**}Short talks from proffered papers.

Transcriptional targeting in cervical cancer **Bhudev C. Das,** Dr. B.R. Ambedakar Centre for Biomedical Research, University of Delhi, New Delhi, India

Genomics of cervical cancer*

Rita Mulherkar

Therapy

Shyam Shrivastava, Tata Memorial Hospital, Mumbai. India

HPV16 E2 potentiates NF- κ B activation induced by TNF- α through STAT3**

Devarajan Karunagaran, Indian Institute of Technology Madras, Chennai, Tamilnadu, India

ADXS11-001 immunotherapy targeting HPV-E7: Preliminary safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer** **Partha Basu,** Chittaranjan National Cancer Institute, Kolkata, India

Discussion

5:50 p.m.-6:20 p.m. Day in Review Pearl Ballroom

Daily wrap-up with Anil K. Rustgi, Rita Mulherkar, Tanuja Teni, and Ashok R. Venkitaraman

6:30 p.m.-7:45 p.m. Professional

Advancement Session: Networking Roundtables

Royal Room

Thursday, December 15

8:00 a.m.-9:30 a.m.

Panel Discussion: Tobacco: Cancer, Chronic Diseases, and Prevention in India

Pearl Ballroom

Chairperson: Ellen R. Gritz, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Introduction

Ellen R. Gritz

Tobacco and cancer epidemiology in India* **Prakash C. Gupta,** Healis-Sekhsaria Institute for Public Health, Mumbai, India

The adverse disease effects of smoking and smokeless tobacco on tuberculosis in India **Nevin C. Wilson,** International Union Against Tuberculosis and Lung Disease (The Union), New Delhi, India

A treetop tour of tobacco control interventions in LMIC*

Mira B. Aghi, Behavioral Scientist, Communication Expert, New Delhi, India

Discussion

9:30 a.m.-10:00 a.m. Break

Central Lobby

10:00 a.m.-11:50 a.m. Plenary Session 4: Breast Cancer

Pearl Ballroom

Co-Chairpersons: Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA, USA; and **Annapoorni Rangarajan,** Indian Institute of Science, Bangalore, India

Clinical genetics and genetic testing **Judy E. Garber**

Epigenetics of hormone dependence

Myles Brown, Dana-Farber Cancer Institute,
Boston, MA, USA

Gene expression signatures in various categories of breast cancer in Indian patients*

Paturu Kondaiah, Indian Institute of Science, Bangalore, India

In vitro transformation of mammospheres generates invasive ductal adenocarcinomas harboring breast cancer cells*

Annapoorni Rangarajan

TMEPAI: A novel drug target in breast cancer therapy and prevention**

Prajjal Kanti Singha, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Acquisition of oxidative stress resistance during the genesis of luminal mammary progenitors is associated with a switch in ROS control mechanisms**

Nagarajan Kannan, Terry Fox Laboratory, Vancouver, BC, Canada

Discussion

12:00 p.m.-2:00 p.m. Poster Session B/Lunch
Prefunction Area

2:10 p.m.-3:40 p.m.

Plenary Session 5: Cancer Prevention and Chemoprevention

Pearl Ballroom

Co-Chairpersons: Raymond N. DuBois, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; and **Ravi Kant,** Maulana Azad Medical College, New Delhi, India

Screening for cervical cancer in low- and middle-income countries

Surendra Shastri, Tata Memorial Hospital, Mumbai, India

Prostaglandin E2 promotes intestinal tumor growth via DNA methylation*

Raymond N. DuBois

Treating tobacco dependence in the oncology setting: A prevention viewpoint*

Ellen R. Gritz, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

A Raman spectroscopy approach for classification of subsites in oral cancers: A feasibility study**

Aditi Sahu, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India

Discussion

3:40 p.m.-4:00 p.m. Break

Central Lobby

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

^{**}Short talks from proffered papers.

4:00 p.m.-5:30 p.m.

Plenary Session 6: Gallbladder Cancer

Pearl Ballroom

Co-Chairpersons: Pramod K. Garg, All India Institute of Medical Sciences, New Delhi, India; and Xifeng Wu, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Epidemiology of gallbladder cancer in India* **Mohandas Mallath,** Tata Memorial Hospital, Mumbai, India

Genetics and molecular pathogenesis of gallbladder cancer*

Balraj Mittal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Chemotherapy in gallbladder carcinoma: Is it really needed?*

Atul Sharma, All India Institute of Medical Sciences, New Delhi, India

Relationship between various biochemical, hematological, comorbid, lifestyle, and demographic parameters in gallbladder carcinoma: A single-center retrospective study of 342 patients**

Rajeev Kumar, Cachar Cancer Hospital and Research Centre, Silchar, Assam, India

Discussion

5:30 p.m.-6:00 p.m. Day in Review

Pearl Ballroom

Daily wrap-up with **Anil K. Rustgi, Raymond N. DuBois, Judy E. Garber,** and **Lalit Kumar**

Friday, December 16

8:00 a.m.-9:00 a.m.

Meet-the-Expert Session

(Concurrent)
Royal Room

Obesity, Inflammation, and Breast Cancer*
Andrew J. Dannenberg, Weill Medical College of
Cornell University, New York, NY, USA

8:00 a.m.-9:00 a.m.

Meet-the-Expert Session

(Concurrent)
Maple Room

Molecular Epidemiology of Cancer: Towards Personalized Risk Assessment, Prevention, and Therapy*

Xifeng Wu, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

9:10 a.m.-9:30 a.m.

Special Lecture

Pearl Ballroom

Cancer Research in India: Future Direction(s)

Vishwa Mohan Katoch, Secretary to the Government of India, Department of Health Research, Ministry of Health and Family Welfare; Director General, Indian Council of Medical Research, New Delhi, India



9:30 a.m.-11:00 a.m.

Plenary Session 7: Chronic Mvelogenous Leukemia

Pearl Ballroom

Co-Chairpersons: Lalit Kumar, All India Institute of Medical Sciences, New Delhi, India; and Hemant Malhotra, Sawai ManSingh Medical College, Jaipur, India

Role of miRNAs in CML*

Soumen Chakraborty, Institute of Life Sciences, Bhubaneswar, Orissa, India

Is CML epidemiology and natural history different in India?

Kumar Prabhash, Tata Memorial Hospital, Mumbai, India

The future of CML in India* **Hemant Malhotra**

Short talks from proffered papers

Discussion

11:00 a.m.-1:00 p.m. Poster Session C/Lunch

Prefunction Area

1:10 p.m.-2:40 p.m.

Plenary Session 8:

Tumor Microenvironment

and Metastasis Pearl Ballroom

Co-Chairpersons: Yves A. DeClerck, University of Southern California, Children's Hospital, Los Angeles, CA, USA; and Sudhir Krishna, National Centre for Biological Sciences, Bangalore, India

EMT-MET in ovarian cancer: Metastable states or distant molecular classes?*

Sharmila A. Bapat, National Centre for Cell Science (NCCS), Pune, India

Exploring the cross talk between Notch and Smad3 in EMT, induction of CD66+ cells, and human cervical cancer progression*

Sudhir Krishna

Bone marrow mesenchymal stem cells and cancer progression in neuroblastoma*

Yves A. DeClerck

Leptin-induced breast cancer growth and metastasis: Functional interactions between leptin signaling, metastasis-associated protein 1(MTA1), and Wnt1 signaling components**

Neeraj Saxena, University of Maryland, Baltimore, MD, USA

Role of tumor microenvironment in the induction of melanoma subpopulations**

Raj Somasundaram, The Wistar Institute, Philadelphia, PA, USA

Discussion

2:40 p.m.-3:10 p.m.

Dav in Review

Pearl Ballroom

Daily wrap-up with Anil K. Rustgi, Hemant Malhotra, and Yves A. DeClerck

3:10 p.m.-3:30 p.m.

Concluding Remarks

Pearl Ballroom

Concluding remarks by Anil K. Rustgi, Judy E.

Garber, and Margaret Foti

^{*}An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.

^{**}Short talks from proffered papers.